Both in Pharmaceuticals
Royalty Pharma vs Alnylam Pharmaceuticals
Over the past year RPRX returned +79.0% and ALNY returned −63.8%; their daily moves had a correlation of 0.19.
RPRX +79.0% ALNY −63.8%Growth of $1, one year, split-adjusted
| Metric | RPRX | ALNY |
|---|---|---|
| Price | $67.18 | $165.00 |
| Market cap | $29.91B | $22.10B |
| Today | +1.90% | −5.17% |
| 1 month | +16.6% | −28.6% |
| 6 months | +35.8% | −44.3% |
| Year to date | +73.9% | −58.5% |
| 1 year | +83.2% | −65.7% |
| Revenue growth (YoY) | +16.5% | +16.7% |
| Gross margin | 100.0% | 75.2% |
| Net margin | 2.7% | 148.6% |
| P/E (TTM) | 36.7× | 8.1× |
| Price / sales | 11.8× | 4.4× |
| Net cash | -$8.23B | $2.57B |
| Dividend yield | 1.40% | — |
| Volatility (60d) | 24.9% | 72.5% |
| Short % of float | 2.9% | 4.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).